Literature DB >> 19359167

Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors.

Shohei Hamada1, Tae-Dong Kim, Takayoshi Suzuki, Yukihiro Itoh, Hiroki Tsumoto, Hidehiko Nakagawa, Ralf Janknecht, Naoki Miyata.   

Abstract

N-Oxalylglycine (NOG) derivatives were synthesized, and their inhibitory effect on histone lysine demethylase activity was evaluated. NOG and compound 1 inhibited histone lysine demethylases JMJD2A, 2C and 2D in enzyme assays, and their dimethyl ester prodrugs DMOG and 21 exerted histone lysine methylating activity in cellular assays.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19359167     DOI： 10.1016/j.bmcl.2009.03.098

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  49 in total

Review 1.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.

Authors:  Zhanxin Wang; Dinshaw J Patel
Journal:  Q Rev Biophys       Date:  2013-09-02       Impact factor: 5.318

2.  Histone demethylases and their roles in cancer epigenetics.

Authors:  Alexandra D'Oto; Qing-Wu Tian; Andrew M Davidoff; Jun Yang
Journal:  J Med Oncol Ther       Date:  2016

3.  Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.

Authors:  Roselyne M Labbé; Andreana Holowatyj; Zeng-Quan Yang
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

Review 4.  The promise and failures of epigenetic therapies for cancer treatment.

Authors:  Pasano Bojang; Kenneth S Ramos
Journal:  Cancer Treat Rev       Date:  2013-07-05       Impact factor: 12.111

5.  Inhibition of histone demethylases by 4-carboxy-2,2'-bipyridyl compounds.

Authors:  Kai-Hsuan Chang; Oliver N F King; Anthony Tumber; Esther C Y Woon; Tom D Heightman; Michael A McDonough; Christopher J Schofield; Nathan R Rose
Journal:  ChemMedChem       Date:  2011-03-15       Impact factor: 3.466

Review 6.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 7.  The role of histone demethylases in cancer therapy.

Authors:  Inga Hoffmann; Martin Roatsch; Martin L Schmitt; Luca Carlino; Martin Pippel; Wolfgang Sippl; Manfred Jung
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

Review 8.  Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX.

Authors:  Kelly Marie Arcipowski; Carlos Alberto Martinez; Panagiotis Ntziachristos
Journal:  Curr Opin Genet Dev       Date:  2016-05-03       Impact factor: 5.578

Review 9.  Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.

Authors:  M L Bellows; C A Floudas
Journal:  Curr Drug Targets       Date:  2010-03       Impact factor: 3.465

10.  Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.

Authors:  Tae-Dong Kim; James R Fuchs; Eric Schwartz; Dalia Abdelhamid; Jonathan Etter; William L Berry; Chenglong Li; Michael A Ihnat; Pui-Kai Li; Ralf Janknecht
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.